Immunogenicity
Among 482 evaluable patients treated with galcanezumab during the double-blind and/or OLE period, 71 (14.7%) had ADAs present at baseline, with 37 patients (7.7%) having neutralizing ADAs. TE-ADAs were detected during galcanezumab treatment in 63 (13.1%) patients, including 59 patients (12.2%) who developed neutralizing ADAs. During the entire study, including the 4-month post-treatment period, 188 galcanezumab-treated patients developed TE-ADAs, including 186 patients (37.6%) who developed neutralizing ADAs. No meaningful relationship was observed between ADAs and efficacy or tolerability of galcanezumab.